Dynavax Technologies (NASDAQ:DVAX) Earns Buy Rating from HC Wainwright

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $29.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 148.93% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They issued a “neutral” rating and a $20.00 target price on the stock. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.33.

Dynavax Technologies Price Performance

DVAX stock opened at $11.65 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. The firm has a market cap of $1.52 billion, a P/E ratio of -194.17 and a beta of 1.30. The firm’s fifty day moving average is $12.06 and its 200 day moving average is $13.03. Dynavax Technologies has a 52 week low of $10.60 and a 52 week high of $15.15.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies during the 3rd quarter valued at $33,000. Advisor Resource Council bought a new stake in Dynavax Technologies during the fourth quarter worth about $144,000. Rathbones Group PLC purchased a new stake in Dynavax Technologies in the third quarter worth about $158,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Dynavax Technologies during the fourth quarter valued at approximately $209,000. Finally, Duality Advisers LP purchased a new position in shares of Dynavax Technologies during the first quarter valued at approximately $227,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.